HA
ONCY

Huntleigh Advisors’s Oncolytics Biotech ONCY Stock Holding History

Huntleigh Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,000
Closed -$11.4K – 299
2025
Q4 		$11.4K Buy
+13,000
New +$14K ﹤0.01% 270

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Huntleigh Advisors's ONCY Position: Q1 2026 in Review

Huntleigh Advisors sold out of Oncolytics Biotech (ONCY) in Q1 2026, closing a stake of 13,000 shares — an estimated $11.4K sold.

Huntleigh Advisors first reported a position in ONCY in Q4 2025 and held it in 1 quarter. The position peaked at $11.4K in Q4 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Huntleigh Advisors reported no remaining Oncolytics Biotech position as of Q1 2026 after selling out during the quarter.
  • Huntleigh Advisors sold 13,000 Oncolytics Biotech shares in Q1 2026, an estimated $11.4K.
  • Huntleigh Advisors first reported a position in Oncolytics Biotech in Q4 2025 and held it in 1 quarter.
  • Huntleigh Advisors's Oncolytics Biotech position peaked at $11.4K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Huntleigh Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.